HomeAI · summaries
Storia in 8 fonti
Pharma stocks slide as Trump's 100% generic drug tariff plan spooks investors
Indian drug shares declined Wednesday following US President Trump's tariff announcement. These proposed tariffs will significantly impact companies with substantial US revenue exposure. Analysts suggest investors should now focus on domestically oriented Indian pharmaceutical firms. The Nifty Pharma index saw a notable decrease, while the benchmark Nifty 50 also fell. Negotiations are expected given India's vital role in supplying affordable medicines to the US.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
timesofindia.indiatimes.com
Trump announces 0% tariff on generic medicines for two years; 200% thereafter
US President Donald Trump on Tuesday announced a phased tariff regime on imported generic medicines, saying they will continue to enter the United States duty-free for two years…
- ·
economictimes.indiatimes.com
Trump announces new generic drugs tariff plan: No tariffs for 2 years, then 100%, and then 200%
Trump has been pressuring drugmakers through his most-favored-nation drug pricing policy to lower prices to what people pay in other high-income countries.
- ·
thehindubusinessline.com
US to impose 100% tariffs on generic medicine imports from Aug 2028
US President Donald Trump on Wednesday announced steep tariffs on imported generic medicines from August 2028, asserting that the move was aimed at onshoring the manufacturing of…
- ·
france24.com
Trump announces 100% tariffs on imported generic pharmaceutical drugs
US President Donald Trump announced a 100% tariff on imported generic pharmaceutical drugs on Tuesday. The tariff, which aims to bolster US pharmaceutical production, is set to go…
- ·
Why these 8 stocks including Pharma majors will remain in focus on today following Trump’s tariff announcement
Maruti Suzuki’s price hike, Anant Raj demerger, Aurobindo Pharma getting nod for bio similar, Anupam Rasayn open offer to Bliss GVS shareholders
- ·
Sun Pharma, Cipla, other pharma stocks in focus as Trump unveils 100%, 200% tariffs on generic drugs from 2028
Indian pharma stocks are likely to remain in focus after US President Donald Trump announced a phased tariff plan for generic medicines, offering a two-year tariff exemption…
- ·
newsbytesapp.com
Trump threatens tariff on generic medicines: Should India be worried?
US President Trump announced a two-year tariff exemption for imported generic medicines, warning of steep 200% duties if production doesn't shift to the US afterward.
- ·
hindustantimes.com
0, 100, 200: How Trump's latest generic medicines tariffs could affect India
Indian drugmakers export around $9-10 billion worth of generic medicines to the American market every year. | India News
- ·
theprint.in
0% now, 100% in 2 years, 200% by 2029—US plan for generic pharma tariffs & what it means for India
US to impose no tariff on generic pharmaceutical goods initially, before hiking to 200%. Announcement set to impact India as US accounts for third of pharma exports from nation.
- ·
Pharma stocks bleed after Trump announces up to 200% tariff on generic drugs; Aurobindo, Sun Pharma & Cipla slide over 3%
Pharmaceutical stocks came under pressure on Wednesday after US President Donald Trump unveiled a phased tariff plan for imported generic medicines, raising concerns over the…
- ·
Trump's Generic Drug Tariffs Explained: What it means for Indian pharma before the 200% storm
Trump's generic drug tariffs plan provides Indian drugmakers a two-year duty-free window. This allows companies time to reassess manufacturing and supply chain strategies. After…
- ·
Pharma stocks decline; Aurobindo Pharma down over 4%
Pharma stocks fall as Aurobindo Pharma drops over 4% following Trump's tariff announcement on imported generic medicines.
- ·
Trump's 200% drug tariff plan: Is India's pharma industry about to face an economic storm?
The United States is set to implement a phased approach to tariffs on generic drug imports, beginning at zero percent and escalating to one hundred percent, eventually reaching…
- ·
Trump’s 100% generic drug duty threatens US low-cost supply
President Donald Trump has given generic drugmakers two years to shift manufacturing to the US or face 100% import tariffs from August 2028, rising to 200% a year later. The move…
- ·
200% Trump tariff shock? India’s cheap pills may still beat US rivals
US President Donald Trump's proposed tariffs of up to 200% on imported generic medicines could put pressure on India's pharmaceutical exporters, but the country's cost advantage…
- ·
Indian pharma firms may yet survive Trump's 200% tariff bombshell
Donald Trump's proposed up to 200% tariff on generic drug imports has raised concerns for Indian pharma companies, but industry experts say the long-term impact may be limited.…
- ·
Explained: What Donald Trump's up to 200% pharma tariffs mean for Indian investors
Donald Trump's announcement of tariffs of up to 200% on pharmaceutical imports triggered a selloff in Indian pharma stocks. However, analysts believe the long-term impact could be…
- ·
Donald Trump’s 200% tariffs on pharma: Why India’s generic medicines could still remain competitive
In a blow to India’s pharmaceutical industry, the Donald Trump administration has announced up to 200% tariffs on generic drugs that will be applicable in the coming years.
- ·
US tariff threat drags Nifty Pharma 1.4% lower; Lupin, Auropharma lead decline
US tariff threats lead to a 1.4% drop in Nifty Pharma, with Lupin and Auropharma experiencing significant declines.
- ·
independent.co.uk
Trump announces plan for 200% tariffs on imported generic drugs
Under the plan, announced on Truth Social, generic drugs imported into the U.S. would remain tariff-free for two years beginning Aug. 1